MXPA02012068A - Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa. - Google Patents

Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.

Info

Publication number
MXPA02012068A
MXPA02012068A MXPA02012068A MXPA02012068A MXPA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A MX PA02012068 A MXPA02012068 A MX PA02012068A
Authority
MX
Mexico
Prior art keywords
synthase inhibitor
thymidylate synthase
liposomal
inhibitor formulations
benzoquinazoline thymidylate
Prior art date
Application number
MXPA02012068A
Other languages
English (en)
Inventor
Gerard M Jensen
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MXPA02012068A publication Critical patent/MXPA02012068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proporcionan formulaciones de inhibidor de la timidilato de benzoquinazolina sintasa encapsuladas, liposomales. Los liposomas tienen farmacocinetica mejorada y mejor eficacia como agentes antitumor en comparacion con el farmaco libre. Las formulaciones incluyen liposomas que comprenden al menos una fosfatidilcolina, un colesterol y un inhibidor de la timidilato de benzoquinazolina sintasa.
MXPA02012068A 2000-06-09 2001-06-06 Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa. MXPA02012068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21059200P 2000-06-09 2000-06-09
PCT/US2001/018224 WO2001095884A2 (en) 2000-06-09 2001-06-06 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations

Publications (1)

Publication Number Publication Date
MXPA02012068A true MXPA02012068A (es) 2004-08-19

Family

ID=22783495

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012068A MXPA02012068A (es) 2000-06-09 2001-06-06 Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.

Country Status (15)

Country Link
US (2) US6689381B2 (es)
EP (1) EP1286661A2 (es)
JP (1) JP2004503491A (es)
KR (1) KR100851957B1 (es)
CN (1) CN1446080A (es)
AU (2) AU2001275269B2 (es)
BR (1) BR0111541A (es)
CA (1) CA2412165A1 (es)
IL (2) IL153230A0 (es)
MX (1) MXPA02012068A (es)
NZ (1) NZ522842A (es)
PL (1) PL360470A1 (es)
TW (1) TWI282741B (es)
WO (1) WO2001095884A2 (es)
ZA (1) ZA200209524B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
JP4758915B2 (ja) * 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
JP4950890B2 (ja) * 2004-09-13 2012-06-13 ギリアード サイエンシーズ， インコーポレイテッド 動物に対する鉄の送達
US20060159735A1 (en) * 2005-01-20 2006-07-20 Nicholas Bonham Method of reclaiming drug compound from liposomal drug manufacturing stream
WO2006078253A1 (en) * 2005-01-20 2006-07-27 Osi Pharmaceuticals, Inc. Method of reclaiming drug compound osi-7904 from liposomal drug manufacturing stream
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
CN100348194C (zh) * 2005-07-26 2007-11-14 康辰医药发展有限公司 盐酸洛拉曲克的脂质体制剂及其制备方法
WO2007111720A2 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US9493810B2 (en) * 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
CA2879139C (en) * 2012-07-18 2021-05-11 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CA3033083A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CA3090387A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
EP0671953A4 (en) 1992-11-13 1996-01-10 Univ Ohio State Res Found ANALOGS OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE ARYLAMIDE.
JPH11199488A (ja) * 1998-01-09 1999-07-27 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤

Also Published As

Publication number Publication date
JP2004503491A (ja) 2004-02-05
IL153230A (en) 2009-02-11
CA2412165A1 (en) 2001-12-20
BR0111541A (pt) 2003-07-01
CN1446080A (zh) 2003-10-01
TWI282741B (en) 2007-06-21
US6689381B2 (en) 2004-02-10
KR20030038552A (ko) 2003-05-16
WO2001095884A3 (en) 2002-06-13
ZA200209524B (en) 2003-11-22
US20020034538A1 (en) 2002-03-21
KR100851957B1 (ko) 2008-08-12
WO2001095884A2 (en) 2001-12-20
PL360470A1 (en) 2004-09-06
AU2001275269B2 (en) 2006-07-13
AU7526901A (en) 2001-12-24
NZ522842A (en) 2004-11-26
US20040057990A1 (en) 2004-03-25
IL153230A0 (en) 2003-07-06
EP1286661A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
MXPA02012068A (es) Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.
NZ513829A (en) Encapsulation of bioactive complexes in liposomes
DE60138566D1 (en) Selbstformende thermodynamisch stabile liposome
WO2002000194A3 (en) Polymeric micelle compositions
AU2001270300A1 (en) Drug delivery formulations and targeting
PL360027A1 (en) Substituted-triazolopyrimidines as anticancer agents
MXPA03001890A (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos.
EP1198256A4 (en) PEPTIDES-LIPIDS CONJUGATES, LIPOSOMES AND SUPPORT OF LIPOSOMIC DRUGS
AU4221400A (en) Fusogenic lipids and vesicles
ZA200200743B (en) Preserved pharmaceutical formulations.
WO1999013816A3 (en) Liposomal camptothecin formulations
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
AU5983900A (en) Combined preparations comprising antitumor agents
AU2001234114A1 (en) Drugs containing combined active ingredients
AU2002236062A1 (en) Lipids, lipid compositions, liposomes, and lipoplexes
EP1154755A4 (en) Liposomes FORMULATIONS
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AUPQ761100A0 (en) Lipophilic medicament
AU2001243515A1 (en) Combination drug therapy
AU2001260270A1 (en) Liposomes containing active substances
EP1308156A4 (en) AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY
WO2002048380A3 (en) Glycosilated cationic lipids for liposomes used in drug delivery
AU2001268653A1 (en) Combination hiv therapy including camptothecin